Tags

Type your tag names separated by a space and hit enter

Cabergoline scavenges peroxynitrite enhanced by L-DOPA therapy in patients with Parkinson's disease.
Eur J Neurol. 2006 Apr; 13(4):346-50.EJ

Abstract

Long-term or high-dose L-DOPA therapy in patients with Parkinson's disease (PD) may accelerate degeneration of dopaminergic neurons, possibly by increasing oxidative stress. To investigate the effects of cabergoline on peroxynitrite-mediated oxidative damage caused by L-DOPA, the concentration of 3-nitrotyrosine in cerebrospinal fluid (CSF) of 18 PD patients was compared with that in 20 normal controls. The concentration of 3-nitrotyrosine in patients following L-DOPA therapy was significantly higher than in untreated PD patients and controls. On the other hand, the concentration in PD patients after cabergoline therapy was significantly lower than in PD patients after L-DOPA therapy alone. These data suggest that cabergoline scavenges peroxynitrite induced by L-DOPA in patients with PD.

Authors+Show Affiliations

Department of Neurology, Iwate Medical University, Morioka, Iwate, Japan. chiso@apost.plala.or.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16643311

Citation

Isobe, C, et al. "Cabergoline Scavenges Peroxynitrite Enhanced By L-DOPA Therapy in Patients With Parkinson's Disease." European Journal of Neurology, vol. 13, no. 4, 2006, pp. 346-50.
Isobe C, Abe T, Kikuchi T, et al. Cabergoline scavenges peroxynitrite enhanced by L-DOPA therapy in patients with Parkinson's disease. Eur J Neurol. 2006;13(4):346-50.
Isobe, C., Abe, T., Kikuchi, T., Murata, T., Sato, C., & Terayama, Y. (2006). Cabergoline scavenges peroxynitrite enhanced by L-DOPA therapy in patients with Parkinson's disease. European Journal of Neurology, 13(4), 346-50.
Isobe C, et al. Cabergoline Scavenges Peroxynitrite Enhanced By L-DOPA Therapy in Patients With Parkinson's Disease. Eur J Neurol. 2006;13(4):346-50. PubMed PMID: 16643311.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cabergoline scavenges peroxynitrite enhanced by L-DOPA therapy in patients with Parkinson's disease. AU - Isobe,C, AU - Abe,T, AU - Kikuchi,T, AU - Murata,T, AU - Sato,C, AU - Terayama,Y, PY - 2006/4/29/pubmed PY - 2006/6/17/medline PY - 2006/4/29/entrez SP - 346 EP - 50 JF - European journal of neurology JO - Eur J Neurol VL - 13 IS - 4 N2 - Long-term or high-dose L-DOPA therapy in patients with Parkinson's disease (PD) may accelerate degeneration of dopaminergic neurons, possibly by increasing oxidative stress. To investigate the effects of cabergoline on peroxynitrite-mediated oxidative damage caused by L-DOPA, the concentration of 3-nitrotyrosine in cerebrospinal fluid (CSF) of 18 PD patients was compared with that in 20 normal controls. The concentration of 3-nitrotyrosine in patients following L-DOPA therapy was significantly higher than in untreated PD patients and controls. On the other hand, the concentration in PD patients after cabergoline therapy was significantly lower than in PD patients after L-DOPA therapy alone. These data suggest that cabergoline scavenges peroxynitrite induced by L-DOPA in patients with PD. SN - 1351-5101 UR - https://www.unboundmedicine.com/medline/citation/16643311/Cabergoline_scavenges_peroxynitrite_enhanced_by_L_DOPA_therapy_in_patients_with_Parkinson's_disease_ L2 - https://doi.org/10.1111/j.1468-1331.2006.01207.x DB - PRIME DP - Unbound Medicine ER -